Evidence map›Paper›PMID 26893477›Full record

ArticleCancer research2016

Activation of the MDA-5-IPS-1 Viral Sensing Pathway Induces Cancer Cell Death and Type I IFN-Dependent Antitumor Immunity.

Xiaofei Yu, Hongxia Wang, Xia Li, Chunqing Guo, Fang Yuan, Paul B Fisher, Xiang-Yang Wang

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Harnessing innate immune pathways for therapeutic advancement in cancer.Signal transduction and targeted therapy · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xiaofei YuDepartment of Human & Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
Hongxia WangDepartment of Human & Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
Xia LiDepartment of Human & Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
Chunqing GuoDepartment of Human & Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
Fang YuanDepartment of Human & Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
Paul B FisherDepartment of Human & Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, Virginia. VCU Institute of Molecular Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia. VCU Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia. xywang@vcu.edu pbfisher@vcu.edu.
Xiang-Yang WangDepartment of Human & Molecular Genetics, Virginia Commonwealth University School of Medicine, Richmond, Virginia. VCU Institute of Molecular Medicine, Virginia Commonwealth University School of Medicine, Richmond, Virginia. VCU Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia. xywang@vcu.edu pbfisher@vcu.edu.
Virginia Commonwealth University · US

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Paula Daniela Bos · 1985 to 2026
$51.0M
Large heat shock proteins and their role in cancer therapyR01CA099326 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI REPASKY, ELIZABETH A, WANG, XIANG-YANG SHAWN · 2003 to 2020
$5.7M
Host-tumor interactions and cancer relapse after radiation therapyR01CA175033 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI WANG, XIANG-YANG SHAWN · 2014 to 2018
$1.6M
Large Stress Proteins in Biology and MedicineR01CA154708 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI WANG, XIANG-YANG SHAWN · 2011 to 2015
$1.5M
NCI NIH HHS P30 CA016059NCI NIH HHS R01 CA099326NCI NIH HHS R01 CA154708NCI NIH HHS R01 CA175033
6 · The paper itself

Abstract

Melanoma differentiation-associated gene 5 (MDA-5, IFIH1), a cytosolic innate pattern recognition receptor, functions as a first line of defense against viral infection by sensing double-stranded RNA. Ectopic expression of MDA-5 has been shown to induce cancer cell death, but the mechanism of action by which MDA-5 exerts these cytotoxic effects is unclear. Here, we demonstrate that ectopic expression of MDA-5 via replication-incompetent adenovirus (Ad.Mda-5) initiates multiple signaling cascades, culminating in cytotoxicity and type I IFN production in mouse and human prostate cancer cells. This intrinsic dual activity of MDA-5 required the adaptor protein IFNβ promoter stimulator 1 (IPS-1, MAVS) and could be functionally uncoupled. MDA-5 lacking N-terminal caspase recruitment domains (CARD) engaged an intracellular death program in cancer cells but was unable to efficiently stimulate the expression of IFNβ. In contrast to cancer cells susceptible to MDA-5-mediated cytotoxicity, normal cells were highly resistant and instead developed a robust type I IFN response. Strikingly, intratumoral delivery of Ad.Mda-5 led to regression of preestablished prostate cancers and development of long-lasting antitumor immune memory, which was primarily attributed to the activation of tumor-reactive cytotoxic T lymphocytes and/or natural killer cells. Using the CARD-truncated MDA-5 mutant, silencing of IPS-1, and antibody blockade of the IFNα/β receptor, we further demonstrate that type I IFN signaling was crucial for in situ MDA-5-induced protective antitumor immunity. Therefore, deliberately targeting the evolutionarily conserved MDA-5-IPS-1 antiviral pathway in tumors can provoke parallel tumoricidal and immunostimulatory effects that bridge innate and adaptive immune responses for the therapeutic treatment of cancer. Cancer Res; 76(8); 2166-76. ©2016 AACR.

Indexed as

Adaptor Proteins, Signal TransducingAdenoviridaeAnimalsApoptosisDefective VirusesHeterograftsHumansInterferon-Induced Helicase, IFIH1Interferon Type IMaleMiceMice, Inbred C57BLProstatic NeoplasmsAdaptor Proteins, Signal TransducingIFIH1 protein, humanInterferon-Induced Helicase, IFIH1Interferon Type IMAVS protein, human

Identifiers

PMID26893477
PMCPMC4873369
OpenAlexW2274785268

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.